ICSBP-Transcript Numbers From CML Patients Treated With IFN-α During Follow-up
Patient No. . | ICSBP-Transcript Levels . | ||
---|---|---|---|
At Diagnosis . | Early IFN-α Treatment . | Late IFN-α Treatment* . | |
1 | − | + | − |
2 | − | + | −/+ |
3 | − | + | ND |
4 | − | −/+ | −/+ |
5 | − | + | − |
6 | − | − | − |
7 | − | + | ND |
8 | − | + | −/+ |
9 | − | + | −/+ |
10 | − | + | − |
11 | − | −/+ | ND |
12 | − | + | − |
Patient No. . | ICSBP-Transcript Levels . | ||
---|---|---|---|
At Diagnosis . | Early IFN-α Treatment . | Late IFN-α Treatment* . | |
1 | − | + | − |
2 | − | + | −/+ |
3 | − | + | ND |
4 | − | −/+ | −/+ |
5 | − | + | − |
6 | − | − | − |
7 | − | + | ND |
8 | − | + | −/+ |
9 | − | + | −/+ |
10 | − | + | − |
11 | − | −/+ | ND |
12 | − | + | − |
Abbreviations: ND, not determined; −, no/low ICSBPexpression; −/+, moderate ICSBP expression; +, highICSBP expression.
Progression of CML.